-
4541
Omentin-1, a Protective Adipokine for Irritable Bowel Syndrome
Published 2025-02-01“…Yanping Gao,1,2,* Chen Chen,1,2,* Xijing Huang,2 Ya Liu,1 Zhou Zhou,1 Yan Pan1 1Department of Gastroenterology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, People’s Republic of China; 2Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yan Pan; Zhou Zhou, Sichuan Provincial People’s Hospital, 32 The First Ring Road West 2, Chengdu, Sichuan, 610072, People’s Republic of China, Email panyan2211@163.com; doublezhou2006@126.comIntroduction: Irritable bowel syndrome (IBS) is characterized by patients’ high level of suffering. …”
Get full text
Article -
4542
Mechanism of Action of Decitabine in the Treatment of Acute Myeloid Leukemia by Regulating LINC00599
Published 2023-01-01Get full text
Article -
4543
-
4544
-
4545
Factors influencing the natural history of non-IgE-mediated gastrointestinal food allergies in paediatric age: a prospective multicentre cohort study
Published 2025-02-01“…Background We aimed at identifying the factors influencing the natural history of non-IgE-mediated gastrointestinal food allergies (non-IgE-GIFA), a group of common paediatric conditions including food protein–induced: enteropathy (FPE), allergic proctocolitis (FPIAP), enterocolitis syndrome (FPIES), and motility disorders (FPIMD).Methods Prospective multicentre cohort study involving paediatric patients (both sexes, aged ≤14 y) with non-IgE-GIFA diagnosed and followed for 24 months at a Tertiary Centre for Paediatric Allergy, Gastroenterology and Nutrition. Anamnestic and clinical data were collected from all enrolled patients.Results 123 non-IgE-GIFA patients were enrolled (56% male, median age (IQR) 150 (60–300) days): FPE (39%), FPIES (17%), FPIAP (16%) and FPIMD (28%). 42% of patients had multiple food allergies (FAs) at baseline, and 64% had a positive family history of allergy. …”
Get full text
Article -
4546
-
4547
-
4548
-
4549
The Effects of Digital eHealth Versus Onsite 2-Day Group-Based Education in 255 Patients With Irritable Bowel Syndrome: Cohort Study
Published 2025-02-01“…MethodsPatients diagnosed with IBS, aged 15-70 years, were enrolled after referral to the Section of Gastroenterology at Haukeland University Hospital, Norway. …”
Get full text
Article -
4550
NKX6.3 modulation of mitotic dynamics and genomic stability in gastric carcinogenesis
Published 2025-01-01Get full text
Article -
4551
-
4552
-
4553
-
4554
Current Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases
Published 2025-01-01Get full text
Article -
4555
Development of a Human Intestinal Organoid Model for In Vitro Studies on Gut Inflammation and Fibrosis
Published 2021-01-01Get full text
Article -
4556
Plant-nanoparticles enhance anti-PD-L1 efficacy by shaping human commensal microbiota metabolites
Published 2025-02-01Get full text
Article -
4557
-
4558
Tolerability and Effectiveness of Regorafenib Treatment in Patients with Unresectable Hepatocellular Carcinoma: Real-World Data from the United States
Published 2025-02-01“…Richard S Finn,1 Renuka Iyer,2 Richard S Kalman,3 Neehar D Parikh,4 Roniel Cabrera,5 Svetlana Babajanyan,6 Ahmed O Kaseb7 1Department of Medicine, University of California, Los Angeles, CA, USA; 2Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA; 3Department of Medicine, Einstein Medical Center, Philadelphia, PA, USA; 4Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA; 5Department of Medicine, University of Florida Health, Gainesville, FL, USA; 6US Medical Affairs, Oncology, Bayer Healthcare, Whippany, NJ, USA; 7Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence: Richard S Finn, Department of Medicine, University of California, Los Angeles, CA, USA, Tel +1-310-586-2091, Email rfinn@mednet.ucla.eduIntroduction: While several systemic therapies are available for unresectable hepatocellular carcinoma (uHCC), there is a lack of granular real-world evidence to support the efficacy and safety of these therapies. …”
Get full text
Article -
4559
Testicular Cancer Presenting as Gastric Variceal Hemorrhage
Published 2017-01-01Get full text
Article -
4560